Ignite Creation Date:
2024-05-05 @ 11:35 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00086138
Status:
COMPLETED
Last Update Posted:
2017-04-11
First Post:
2004-06-25
Brief Title:
Depression in Alzheimers Disease-2
Sponsor:
Johns Hopkins University
Organization:
Johns Hopkins University
Study Overview
Official Title:
Depression in Alzheimers Disease DIADS-2
Status:
COMPLETED
Status Verified Date:
2017-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
DIADS-2
Brief Summary:
The purpose of this study is to learn whether treating individuals with Alzheimers disease and depression with the anti-depressant medication sertraline Zoloft is helpful to people with Alzheimers disease and to their families and caregivers
Detailed Description:
Participants are randomly assigned to treatment with sertraline range 25-125 mg per day or identical placebo for 24 weeks There are 8 scheduled in-person visits in the 24 weeks Visits include neuropsychological testing Caregivers are asked to are the patient on a Daily Affect Diary for 6 weeks during the study period Telephone followup is done at weeks 36 and 48 Both groups receive caregiver supporteducation
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| DATR A4-GPX | US NIH GrantContract | None | httpsreporternihgovquickSearchU01MH066136 |
| U01MH066136 | NIH | None | None |